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Biomedical Advanced Research 
and Development Authority
BARDA’s mission is to support development and availability of 
countermeasures for CBRN threats, pandemic influenza, and 
emerging infectious diseases through advanced product 
development, stockpile acquisition/building, manufacturing 
infrastructure building, and product innovation.
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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• Establish and maintain a 
dynamic vaccine stockpile 
against influenza strains 
with pandemic potential  
available for up to 20 M 
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
National Strategy for 
Pandemic Influenza






• Provide pandemic vaccine 
to all U.S. citizens within 6 
months of a pandemic 
declaration (600 M doses) 
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Pre-2003 Pandemic Influenza 
Vaccine Goal & Strategy 
Egg-based 
Vaccines



























Infrastructure Building  
4 contracts, 7 grants/IAAs
Egg-based Supply
Retrofit Existing Mfg Facilities
Build New Mfg Facilities
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3 contracts
(11 contracts)







Vaccine Candidates & Assays
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MORE
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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Build on Existing Egg-based 
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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Technology
In the beginning…….. 
…at BARDA, the egg came first!
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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• The most attainable goal for near term pandemic 
preparedness
─ Egg Supply Contract (2004)
• Established a year round supply of fertilized eggs for influenza 
vaccine manufacturing
• Created inventories of other essential supplies (vials, preservative, 
etc.)
Egg-based Technology Investments
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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─ Vaccine Stockpile Contracts (2004)
• Contracts to produce vaccine for pre-pandemic stockpile and in the 
event of a pandemic (2009)
• Manufacturing base gains experience producing pandemic virus 
vaccine at commercial scale
─ Facility Retrofit Contracts (2007)
• Expanded domestic facilities for inactivated and live-attenuated 
influenza vaccine production
BETTER
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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Newer Influenza Vaccine 




• Provide more robust, flexible, and scalable                            
process for manufacturing influenza vaccines
• Awarded 6 contracts in 2005-06 for advanced 
development of US licensed cell-based seasonal
& pandemic influenza vaccines with commitment for domestic 
surge capacity of 150M doses within 6 mos. of pandemic onset
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
• Novartis, Baxter, sanofi pasteur, GSK, Solvay, MedImmune
─ One manufacturer filed their BLA in October 2012
─ One completed pivotal Phase 3 clinical studies & expected to 
submit a BLA in 2012-13
─ One manufacturer in early stage development
─ Three programs are no longer active
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• Adjuvants, immunostimulating molecules, provide dose-sparing effects, cross-strain protection
(in animal models) and reactivity in serological assays, and enhanced immune responses to 
vaccines  
• ASPR/BARDA awarded 3 contracts in 2007 ($133 M) for advanced development of US-licensed 
pandemic influenza vaccines with adjuvants
─ Novartis, GSK, Intercell (formerly IOMAI)
─ One manufacturer (GSK) has completed Phase 3 clinical studies & submitted a BLA in 
February 2012
─ One manufacturer has completed Phase 2 clinical studies
─ One contract is no longer active
Antigen-sparing 
Adjuvant Technologies
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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< filled vaccine & adjuvant – Production skid >
• Mix-n-Match program with NIH
─ H1N1 program with sanofi pasteur antigen and GSK adjuvant completed
─ H5N1 program with sanofi pasteur antigen and GSK & Novartis adjuvants
• IND filed December 2010 and clinical testing started Q2 2011
Public Private Partnership Changed 
U.S. Vaccine Industry 
ASPR: Resilient People. Healthy Communities. A Nation Prepared. 14
First cell-based influenza vaccine mfg. facility in the U.S. (Novartis):
Dedicated as Pandemic Ready in December 2011
FASTER
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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Technology Innovation for 
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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Influenza Vaccines
Recombinant & Molecular Vaccine 
Technologies
• Recombinant & molecular technologies may 
provide vaccine sooner with less dependence 
on influenza virus strain properties
• BARDA awarded contracts in 2009 & 2011 for advanced 
development of US-licensed recombinant- based seasonal & 
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
pandemic influenza vaccines with commitment for domestic 
manufacturing surge capacity of 50 M doses in 6 months of 
pandemic onset & initial lot release in 12 weeks
• Protein Sciences, Novavax, & VaxInnate
─ One manufacturer completed Phase 3 clinical trials & BLA 
submitted
─ Two manufacturers in Phase 2 clinical studies
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• Build or Retrofit Manufacturing Facilities
─ Newly constructed or retrofitted existing facilities in the U.S. will utilize state-of-the art 
flexible manufacturing approaches for platform vaccine and biopharmaceutical product 
technologies
• Provide ADM Core Services for CBRN\ID MCMs 
─ Upstream & downstream process development, optimization, scale up, and validation
─ Manufacturing process validation
─ Product formulation chemistry
─ Lot release & clinical testing assay development, optimization, and validation
Centers for Innovation in Advanced 
Development and Manufacturing
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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─ Quality systems (Control & Assurance – GMP & GLP compliance)
─ Regulatory affairs (IND, EUA, BLA, NDA submissions & strategy)
─ Clinical investigational lot manufacturing (pilot scale)
─ Commercial scale manufacturing
─ Program management
• Workforce Development Training Program 
• Provide Emergency Flexible Vaccine Manufacturing for Pan Flu & Other 
Threats
– Pandemic influenza vaccine manufacturing capacity should be at least 50 million doses
BARDA Core Services
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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Selected PCAST and 
MCER Recommendations
• Interagency Initiatives: 
(BARDA, CDC, FDA, NIH) 
+ Industry
─ Establish HHS interagency 
program with industry to 
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
optimize influenza virus vaccine 
strains for production yield 
─ Develop faster potency & 
sterility assays
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Pandemic Influenza Vaccine 
Gap Closure Goals - 2012
Egg- & Cell-
based Vaccines + 
Adjuvants

































BARDA has used a staged approach to build a 
sustainable influenza vaccine enterprise for 
pandemic preparedness by investing in 
technologies that produce:





• Quadrivalent Seasonal Influenza Vaccines
─ 29 Feb 2012: MedImmune FluMist Quadrivalent influenza vaccine licensed by the 
FDA for active immunization of individuals 2 through 49 years of age 
(http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm)
─ 01 Mar 2012: Novavax announces ongoing enrollment of Ph2 trial for quadrivalent
seasonal influenza virus-like particle vaccine 
(http://www.novavax.com/download/releases/Novavax%20Launches%20Phase%202%20Seasonal%20Flu%20Study.pdf)
─ 05 Mar 2012: GSK submitted US and EU regulatory applications for a quadrivalent
influenza vaccine (http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-963574.htm)
• Pre-pandemic Vaccines
─ 02 Mar 2012: Baxter receives marketing authorization in EU for Vepacel
“Hot off the press” or 
“This just tweeted” in 2012
ASPR: Resilient People. Healthy Communities. A Nation Prepared.
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pre-pandemic influenza vaccine – first approved Vero cell vaccine
─ 05 Mar 2012: GSK submitted US and EU regulatory applications for a H5N1 
influenza vaccine (http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-963574.htm)
─ Mar 2012: Novavax starts two Phase 1 clinical studies with adjuvanted H5N1 
influenza virus-like particle vaccine (http://www.novavax.com/go.cfm?do=Press.List&Year=2012)
• Universal Influenza Vaccines
─ 31 Jan 2012: Inovio shows cross-strain immune responses in animals generated by 
SynCon® consensus sequence DNA vaccine
─ 23 Feb 2012: Biondvax Phase IIa with elderly volunteers. Created immune response 
alone and improved immune response when used as a booster.
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